Supernus and Indivior announce all-stock merger of equals to create CNS-focused biopharma company

SUPERNUS PHARMACEUTICALS, INC.

All-stock merger of equals between Supernus and Indivior; combined company to have four established CNS/behavioral health franchises.
Jack Khattar (Supernus CEO) to serve as CEO of combined company; transaction expected to close in Q4 2026.
Combined portfolio includes SUBLOCADE (opioid use disorder), Qelbree (ADHD), Zurzuvae (postpartum depression), Onapgo and GOCOVRI (Parkinson's).
Merger intended to create financial strength and flexibility for business development; integration planning to be structured.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.